GLK-2SD is under clinical development by GL Pharm Tech and currently in Phase I for Diabetes. According to GlobalData, Phase I drugs for Diabetes have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GLK-2SD’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GLK-2SD overview

GLK-2SD is under development for the treatment of diabetes. It is an incrementally modified drug (IMD).

GL Pharm Tech overview

GL Pharm Tech (GLPHarmTech) is a pharmaceutical company that offers drug formulations and delivery technologies. The company offers modified drugs and generic drugs. It offers products under the brands G-SOREN, Olmetec, Lipitor, Caduet, Splendi, Zanidip and Cozaar, among others. GLPHarmTech’s products are used in the treatment of various therapeutic areas which include melasma, diabetes, emergency contraceptive, birth control, endometriosis, hypertension, benign prostatic hyperplasia (BPH) and hormone replacement therapy (HRT), among others. The company works in collaboration with domestic and foreign pharmaceutical companies. It markets products through its partners and distributors. GLPHarmTech is headquartered in Seongnam, South Korea.

For a complete picture of GLK-2SD’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.